Silk Road Medical, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:19 pm EST
Share
Silk Road Medical, Inc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 44.44 million compared to USD 37.37 million a year ago. Net loss was USD 12.79 million compared to USD 10.32 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.29 a year ago.
For the nine months, sales was USD 129.86 million compared to USD 98.57 million a year ago. Net loss was USD 42.73 million compared to USD 42.4 million a year ago. Basic loss per share from continuing operations was USD 1.1 compared to USD 1.21 a year ago.
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
SILK ROAD MEDICAL, INC 
